Paladin Labs Announces the Canadian Launch of Veregen®

MONTREAL, July 16, 2014 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo 
International plc (Nasdaq: ENDP) (TSX: ENL) and a leading Canadian specialty 
pharmaceutical company, today announced the launch of Veregen® 
(sinecatechins) Ointment, 10%, a topical treatment for external genital and 
perianal warts (condylomata acuminata) in immunocompetent patients aged 18 
years and over. 
Clinically visible warts are present in approximately 1% of sexually active 
adults, making genital warts the most common sexually transmitted 
infection(1).  Studies have demonstrated that for individuals with external 
genital warts, the reduction in their quality of life is of similar magnitude 
to that seen in people with moderate to severe asthma or osteoarthritis(2). 
"We are pleased to announce the launch of Veregen® in Canada," said Mark 
Beaudet, President of Paladin Labs Inc. "Sexually transmitted infections 
(STIs) such as external genital warts can cause tremendous psychological 
stress(3).  Canadians who suffer from external genital warts now have a new, 
non-invasive and effective topical treatment option with a demonstrated 
tolerability profile." 
Paladin obtained the exclusive rights to market Veregen® in Canada from 
Medigene AG in May 2014. 
About Veregen: Veregen® (sinecatechins) Ointment 10% is a topical treatment 
for external genital and perianal warts (condylomata acuminata) in 
immunocompetent patients aged 18 years and over.  It is available in a 15g 
tube.  The drug substance in Veregen® is sinecatechins, which is a partially 
purified fraction of the water extract of green tea leaves from Camellia 
sinensis (L.) O Kuntze and is a mixture of catechins and other green tea 
components.  The most common side effects with Veregen® Ointment are local 
skin and application site reactions, but these should decrease over time(4). 
Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012 
European Guideline for the Management of Anogenital Warts.  In addition, in 
its current treatment guidelines for sexually transmitted diseases, the US 
Center for Disease Control and Prevention recommends Sinecatechins 15% 
Ointment (Veregen®) as a possible option for treating genital warts. 
About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada, 
is a specialty pharmaceutical company focused on acquiring or in-licensing 
innovative pharmaceutical products for Canadian and select emerging markets. 
Paladin has a focused marketing and sales organization that has helped it 
evolve into one of Canada's leading specialty pharmaceutical companies. 
Paladin is an operating company of Endo International plc, a global specialty 
healthcare company focused on improving patients' lives while creating 
shareholder value.  Learn more at 
1. Society of Obstetricians and Gynaecologists of Canada. Canadian 
 consensus guidelines on human papillomavirus. J Obstet Gynaecol 
 Can 2007;29(8 Suppl 3):S1-56.
  2. F. Marra, G. Ogilivie, L. Colley, E. Kliewer, C.A. Marra. 
 Epidemiology and costs associated with genital warts in Canada. 
 Sex Transfm Infect 2009;85:111 - 115.
  3. G. Mortenson, H. Larsen. The quality of life of patients with 
 genital warts: a qualitative study. BMC Public Health 2010, 
  4. Veregen® Product Monograph. Triton Pharma Inc., August 27, 2013. 
Forward-Looking Statements 
Cautionary Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of 
the Private Securities Litigation Reform Act of 1995 and Canadian securities 
legislation. Statements including words such as "believes," "expects," 
"anticipates," "intends," "estimates," "plan," "will," "may," "look forward," 
"intend," "guidance," "future" or similar expressions are forward-looking 
statements. Because these statements reflect Endo's current views, 
expectations and beliefs concerning future events, these forward-looking 
statements involve risks and uncertainties. Although Endo believe that these 
forward-looking statements and information are based upon reasonable 
assumptions and expectations, readers should not place undue reliance on them, 
or any other forward-looking statements or information in this news release. 
Investors should note that many factors, as more fully described in the 
documents filed by Endo and Endo Health Solutions Inc. ("EHSI") with 
securities regulators in the United States and Canada including under the 
caption "Risk Factors" in EHSI's Form 10-K, and Endo's Form 10-Q and Form 8-K 
filings, as applicable, with the Securities and Exchange Commission and by 
Endo with securities regulators in Canada on the System for Electronic 
Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein 
or therein, could affect Endo's future financial results and could cause 
Endo's actual results to differ materially from those expressed in 
forward-looking statements contained in EHSI's Annual Report on Form 10-K. The 
forward-looking statements in this press release are qualified by these risk 
factors. These are factors that, individually or in the aggregate, could cause 
Endo's actual results to differ materially from expected and historical 
results. Endo does not assume any obligation to publicly update any 
forward-looking statements, whether as a result of new information, future 
developments or otherwise, except as may be required under applicable 
securities law.

SOURCE  Endo International plc 
Investors/Media: Blaine Davis, +353-1-669-6635, (484) 216-7158; Investors: 
Jonathan Neely, (484) 216-6645; Media: Brian O'Donnell, (484) 216-6726 
CO: Paladin Labs Inc.
ST: Quebec
-0- Jul/16/2014 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.